Ignite Creation Date:
2025-12-24 @ 7:22 PM
Ignite Modification Date:
2026-03-11 @ 5:02 PM
Study NCT ID:
NCT02837003
Status:
UNKNOWN
Last Update Posted:
2016-08-02
First Post:
2016-07-08
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
Sponsor:
Teikyo University
Organization:
Study Overview
Official Title:
3-Month Discontinuation of Dual Antiplatelet Therapy After Ultimaster Sirolimus-Eluting Stent Implantation
Status:
UNKNOWN
Status Verified Date:
2016-07
Last Known Status:
RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
MODEL U-SES
Brief Summary:
To evaluate safety of reduction of dual antiplatelet therapy period to three months after implantation of Ultimaster sirolimus-eluting stent (U-SES).
Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.
Additionally to investigate appropriateness of thienopyridine monotherapy with discontinuation of aspirin.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
True
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?: